These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2702801)

  • 21. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation.
    Zhou HH; Anthony LB; Roden DM; Wood AJ
    Clin Pharmacol Ther; 1990 Jun; 47(6):686-93. PubMed ID: 2357863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
    Siddoway LA; Thompson KA; McAllister CB; Wang T; Wilkinson GR; Roden DM; Woosley RL
    Circulation; 1987 Apr; 75(4):785-91. PubMed ID: 3829342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
    Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.
    Jonkers RE; Koopmans RP; Portier EJ; van Boxtel CJ
    J Pharmacol Exp Ther; 1991 Mar; 256(3):959-66. PubMed ID: 1848636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
    Sanz EJ; Villén T; Alm C; Bertilsson L
    Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methoxyphenamine O-demethylase and 5-hydroxylase: a GLC-ECD assay to study their activities and their inhibition by debrisoquine and sparteine.
    Hawes EM; Roy SD; McKay G; Midha KK
    Pharmacol Ther; 1987; 33(1):73-7. PubMed ID: 3628478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Debrisoquin oxidation polymorphism in a Spanish population.
    Benítez J; LLerena A; Cobaleda J
    Clin Pharmacol Ther; 1988 Jul; 44(1):74-7. PubMed ID: 3391005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
    Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites.
    Walle T; Walle UK; Cowart TD; Conradi EC; Gaffney TE
    J Pharmacol Exp Ther; 1987 Jun; 241(3):928-33. PubMed ID: 3598909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proceedings: Parasympathetic blockade in patients treated with debrisoquine and with propranolol.
    Aminu J
    West Afr J Pharmacol Drug Res; 1974 Dec; 2(1):53P-54P. PubMed ID: 4470635
    [No Abstract]   [Full Text] [Related]  

  • 33. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
    Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
    Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No correlation between side-chain of propranolol oxidation and S-mephenytoin 4'-hydroxylase activity.
    Xie HG; Xu ZH; Huang SL; Liu JH; Wu JX; Jiang CH; Zhou HH
    Zhongguo Yao Li Xue Bao; 1997 May; 18(3):216-8. PubMed ID: 10072936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alfentanil clearance is independent of the polymorphic debrisoquin hydroxylase.
    Henthorn TK; Avram MJ; Krejcie TC
    Anesthesiology; 1989 Nov; 71(5):635-9. PubMed ID: 2817455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes.
    Masubuchi Y; Kagimoto N; Narimatsu S; Fujita S; Suzuki T
    Drug Metab Dispos; 1993; 21(6):1012-6. PubMed ID: 7905378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct high-performance liquid chromatographic determination in urine of the enantiomers of propranolol and its major basic metabolite 4-hydroxypropranolol.
    Herring VL; Johnson JA
    J Chromatogr; 1993 Feb; 612(2):215-21. PubMed ID: 8468379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partial metabolic clearances as determinants of the oral bioavailability of propranolol.
    Walle T; Walle UK; Olanoff LS; Conradi EC
    Br J Clin Pharmacol; 1986 Sep; 22(3):317-23. PubMed ID: 3768243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.